Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADC’s Label-Expansion Study For Zynlonta Halted For Respiratory Safety

Executive Summary

A Phase II study in a frail, older lymphoma population has seen seven respiratory-related deaths along with five other serious adverse events, but so far Zynlonta has been deemed not related to the AEs.

You may also be interested in...



ADC Therapeutics To Wind Up Zynlonta Study In Frail Patients After Deaths

The company had hoped its antibody drug conjugate could help frail and elderly B-cell lymphoma patients ineligible for chemotherapy, but the trial will now close following patient deaths.

Finance Watch: Royalty Deals Pick Up As Alternative Financings Find Appeal

Public Company Edition: Seven companies revealed $2.1bn worth of royalty financings in the first quarter of 2023 and the deals keep coming in Q2, with uniQure monetizing Hemgenix royalties for up to $400m. Also, Legend grossed $350m in a follow-on offering and Athenex is liquidating via bankruptcy. 

Sobi To Start Selling Zynlonta After Sealing EU Approval

Five months after paying $55m upfront to Switzerland's ADC Therapeutics, Sobi has been granted conditional marketing authorization for Zynlonta for the treatment of relapsed or refractory diffuse large B-cell lymphoma.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148683

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel